Moleculin Biotech, Inc. (MBRX) by event type
MBRX moves most on rating reiterations — a median of -0.59% at 30 minutes across 23 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the MBRX overview →
How MBRX reacts across 2 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations 549 of 2,283 | 70 | +0.33% | 51% | -0.61% |
| Rating reiterations 3,349 of 3,522 | 23 | -0.59% | 35% | -2.38% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how MBRX usually reacts — get an email when it moves on news →Every name measured for these event types: Coverage initiations → · Rating reiterations → · MBRX overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) | 427 | -0.21% | 39% |
| Veracyte, Inc. (VCYT) | 427 | -0.15% | 46% |
| Summit Therapeutics Inc. (SMMT) | 426 | +0.03% | 50% |
| Scholar Rock Holding Corporation (SRRK) | 425 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.